RNAi技術の世界市場 - 世界の産業規模、シェア、動向、機会、および予測、2018年～2028年、タイプ別、用途別、エンドユーザー別、地域別、競合分析

世界のRNAi技術市場は2022年に10億8,000万米ドルと評価され、2028年までのCAGRは9.89%で、予測期間中に力強い成長が予測されています。

世界のRNAi技術市場は、バイオテクノロジーと製薬業界の中でダイナミックかつ急速に発展している分野です。遺伝子制御と治療法開発のための強力なツールであるRNA干渉（RNAi）技術は、世界中で大きな支持を得ています。この市場概要では、急成長するこの分野の主要な側面を簡潔に垣間見ることができます。RNAi技術は、低分子RNAを用いて標的遺伝子の発現を抑制することで、特定の遺伝子のサイレンシングを可能にする生物学的プロセスです。RNAi技術は、遺伝子の機能と制御に関する我々の理解に革命をもたらし、創薬、機能ゲノミクス、個別化医療に新たな道を開いた。世界のRNAi技術市場は、遺伝子治療、医薬品開発、農業、研究ツールなど幅広い用途を包含しています。この市場成長の主な促進要因のひとつは、創薬・薬剤開発における極めて重要な役割です。RNAiベースの治療薬は、がん、ウイルス感染、遺伝性疾患など様々な疾患の治療において計り知れない可能性を示しています。製薬会社はRNAiベースの医薬品候補への投資を増やしており、市場の拡大に拍車をかけています。

さらに、機能ゲノミクスにおけるRNAi技術の応用は、遺伝子機能、シグナル伝達経路、疾患メカニズムの理解を促進しています。このことは、より的を絞った効果的な治療法の開発につながり、研究開発活動を後押ししています。ヘルスケアへの応用に加え、農業分野でも作物の改良や害虫駆除にRNAi技術が採用されています。RNAiベースの作物保護ソリューションを開発することで、農家は収穫量を増やし、化学農薬の必要性を減らすことができ、持続可能な農業の実践に貢献します。世界のRNAi技術市場は、主要企業間の熾烈な競争と継続的な技術進歩を特徴としています。各社は研究能力を強化し、製品ポートフォリオを拡大するため、共同研究、提携、合併に取り組んでいます。さらに、規制当局の承認と知的財産権は、この市場の情勢を形成する上で極めて重要な役割を果たしています。

市場促進要因

RNAiベースの治療薬に対する需要の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のRNAi技術市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タイプ別（マイクロRNA、小分子干渉RNA、その他）
  • 用途別（治療タイプ、治療薬、ドラッグデリバリー、農業、その他）
  • エンドユーザー別（研究・学術研究所、診断研究所、その他）
  • 企業別（2022年）
  • 地域別
• 市場マップ

第6章 北米のRNAi技術市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のRNAi技術市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋のRNAi技術市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のRNAi技術市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのRNAi技術市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のRNAi技術市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Alnylam Pharmaceuticals, Inc
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Current Capacity Analysis
  • Financials（In case of listed）
  • Recent Developments
  • SWOT Analysis
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics
• Phio Pharmaceuticals
• Benitec Biopharma
• Novartis AG
• AstraZeneca
• Silence Therapeutics
• Arbutus Biopharma
• Sylentis S.A.

第16章 戦略的提言

Global RNAi Technology Market has valued at USD 1.08 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.89% through 2028. The Global RNAi Technology Market is a dynamic and rapidly evolving sector within the biotechnology and pharmaceutical industries. RNA interference (RNAi) technology, a powerful tool for gene regulation and therapeutic development, has gained significant traction worldwide. This market overview will provide a concise glimpse into the key facets of this burgeoning field. RNAi technology is a biological process that enables the silencing of specific genes by using small RNA molecules to inhibit the expression of targeted genes. It has revolutionized our understanding of gene function and regulation, opening up new avenues for drug discovery, functional genomics, and personalized medicine. The global RNAi technology market encompasses a wide range of applications, including gene therapy, drug development, agriculture, and research tools. One of the primary drivers of this market's growth is its pivotal role in drug discovery and development. RNAi-based therapeutics have shown immense potential in treating various diseases, including cancer, viral infections, and genetic disorders. Pharmaceutical companies are increasingly investing in RNAi-based drug candidates, fueling the market's expansion.

Moreover, the application of RNAi technology in functional genomics has expedited the understanding of gene functions, signaling pathways, and disease mechanisms. This has led to the development of more targeted and efficacious therapies, driving research and development activities. In addition to healthcare applications, the agricultural sector has also embraced RNAi technology for crop improvement and pest control. By developing RNAi-based crop protection solutions, farmers can enhance yield and reduce the need for chemical pesticides, contributing to sustainable agriculture practices. The global RNAi technology market is characterized by intense competition among key players and continuous technological advancements. Companies are engaged in collaborations, partnerships, and mergers to bolster their research capabilities and expand their product portfolios. Furthermore, regulatory approvals and intellectual property rights play a crucial role in shaping the landscape of this market

Key Market Drivers

Growing Demand for RNAi-based Therapeutics

The growing demand for RNAi-based therapeutics is a pivotal driver significantly boosting the Global RNAi Technology Market. RNA interference (RNAi) has emerged as a transformative approach in the field of medicine, offering precise and targeted solutions for a wide range of diseases. This increasing demand is primarily fueled by several key factors. First and foremost, RNAi-based therapeutics hold the promise of revolutionizing the treatment of various chronic and genetic diseases. These therapeutics operate at the genetic level, silencing or modulating the expression of specific genes associated with diseases like cancer, viral infections, and neurodegenerative disorders. As the global incidence of these diseases continues to rise due to factors such as aging populations and changing lifestyles, the need for more effective, targeted, and less invasive treatment options has never been greater. Furthermore, RNAi-based drugs offer a personalized medicine approach that caters to individual patient profiles. By specifically targeting the genetic drivers of diseases, RNAi-based therapies can potentially minimize side effects and improve treatment outcomes. This patient-centric approach aligns with the evolving landscape of healthcare, where precision medicine is gaining momentum.

The successful approval and commercialization of RNAi-based drugs, such as Onpattro® for hereditary transthyretin amyloidosis, have paved the way for increased confidence in the technology's therapeutic potential. Pharmaceutical companies are actively investing in RNAi research and development, with a robust pipeline of RNAi-based drug candidates under investigation. This influx of investments and drug development activities has led to a surge in research and innovation in the field. Moreover, RNAi technology's versatility extends beyond therapeutic applications into functional genomics, target validation, and drug discovery. Researchers and pharmaceutical companies are leveraging RNAi to better understand gene functions, signaling pathways, and potential drug targets, further fueling the demand for RNAi technology and its applications.

Rising Incidence of Chronic Diseases

The Global RNAi Technology Market is experiencing substantial growth, largely attributable to the rising incidence of chronic diseases worldwide. Chronic diseases, including cancer, diabetes, cardiovascular diseases, and neurodegenerative disorders, have become a global health crisis, prompting a significant shift in the healthcare landscape. RNA interference (RNAi) technology is emerging as a potent tool to address the underlying genetic factors contributing to these diseases, making it a key driver in the market's expansion. The escalating prevalence of chronic diseases can be attributed to various factors, such as an aging population, unhealthy lifestyle choices, and environmental factors. As these diseases continue to exact a heavy toll on both individuals and healthcare systems, there is an urgent need for innovative and more effective therapeutic interventions. RNAi-based therapeutics offer a promising avenue to tackle chronic diseases at their genetic roots.

RNAi technology enables the precise and targeted modulation of gene expression, allowing for the silencing of genes responsible for disease progression. By developing RNAi-based therapies, pharmaceutical companies are striving to provide more effective treatments with fewer side effects. This approach aligns with the paradigm shift towards personalized medicine, where therapies are tailored to an individual's genetic makeup, ultimately improving treatment outcomes and patient quality of life. Furthermore, RNAi technology's potential extends to a wide range of chronic diseases. For instance, in oncology, RNAi can be used to target specific genes involved in tumor growth and metastasis, offering a potential breakthrough in cancer treatment. In diabetes, RNAi can be employed to regulate insulin production and glucose metabolism, providing innovative approaches to managing this chronic condition. The growing demand for RNAi-based therapeutics to address the rising incidence of chronic diseases is driving extensive research and development efforts..

Advancements in Delivery Systems

Advancements in delivery systems are playing a pivotal role in propelling the Global RNAi Technology Market to new heights. One of the longstanding challenges in RNA interference (RNAi) technology has been the efficient and targeted delivery of RNAi molecules to specific cells and tissues within the body. However, recent innovations in delivery systems have significantly improved the viability and effectiveness of RNAi-based therapies, driving the market's expansion. The success of RNAi-based therapeutics hinges on the ability to safely transport small RNA molecules, such as siRNA or miRNA mimics, to their intended targets while avoiding off-target effects and degradation. LNPs have emerged as a leading delivery vehicle for RNAi molecules. These nanoparticles encapsulate and protect RNAi payloads, facilitating their transport to target cells. LNPs have shown high efficiency in delivering RNAi therapies to hepatocytes, enabling the development of drugs like Onpattro® for hereditary transthyretin amyloidosis. Further refinements in LNP formulations are ongoing to enhance their versatility and applicability to various tissue types.

Viral vectors, such as adeno-associated viruses (AAVs), have gained prominence for their ability to deliver RNAi molecules to specific tissues with exceptional precision. AAV-based delivery systems have demonstrated success in targeting the central nervous system and are being explored for applications in neurodegenerative diseases. Nanoparticle-based carriers, including polymeric nanoparticles and inorganic nanoparticles, offer tailored solutions for RNAi delivery. These carriers can be engineered to overcome biological barriers and deliver RNAi payloads to specific cells or tissues, opening up opportunities for a wide range of applications. The progress in delivery systems has catalyzed increased investment in RNAi research and development, with pharmaceutical companies and biotech firms actively pursuing RNAi-based drug candidates across multiple therapeutic areas. Furthermore, the successful clinical translation of RNAi therapies and their subsequent regulatory approvals have reinforced the confidence in these delivery systems.

Key Market Challenges

Off-Target Effects

RNA interference (RNAi) technology has garnered significant attention for its potential to revolutionize the treatment of various diseases and advance scientific research. However, one major hurdle that has been hindering the progress of the Global RNAi Technology Market is the challenge of off-target effects Off-target effects can result in unpredictable outcomes, which is especially problematic in therapeutic applications. When unintended genes are affected, it can lead to adverse effects, including toxicity, altered cellular functions, or the exacerbation of underlying diseases. Ensuring the safety of RNAi-based therapies is paramount. Off-target effects can trigger immune responses and result in unintended consequences, which may compromise the overall safety profile of RNAi molecules. This concern has led to extensive safety assessments in preclinical and clinical studies, adding complexity and cost to the development process.

Developing RNAi therapeutics requires precise targeting of disease-associated genes. The risk of off-target effects necessitates meticulous design and validation of RNAi molecules to minimize the potential for unintended gene silencing. This can slow down the drug development process and increase the associated costs. Off-target effects can also interfere with the normal function of genes that are not associated with disease. In research applications, this can lead to misleading results and hinder our understanding of gene function and regulatory pathways...

Immune Response and Toxicity

One of the primary concerns in the development of RNAi-based therapies is the potential for triggering an immune response. When synthetic RNA molecules, such as small interfering RNAs (siRNAs) or microRNAs (miRNAs), are introduced into the body, the immune system may recognize them as foreign invaders, leading to an immune response. This immune activation can result in inflammation and, in some cases, adverse effects on the patient. Toxicity associated with RNAi technology is another significant challenge. The introduction of RNA molecules into cells can disrupt normal cellular processes, leading to unintended toxic effects. These effects may include cell damage, altered gene expression, and even cell death. Toxicity concerns can compromise patient safety and the overall viability of RNAi-based therapeutics.

Delivery methods used to transport RNAi molecules to their target cells can also contribute to toxicity concerns. Some delivery systems may introduce materials or components that are toxic to cells or tissues, further complicating the safety profile of RNAi technology. Ensuring the long-term safety of RNAi-based therapies is crucial, especially for chronic diseases that require continuous treatment. Potential immune responses and toxicity issues must be carefully monitored over extended periods to assess the therapy's safety and efficacy.

Key Market Trends

Precision Medicine and Personalized Therapies

The paradigm shift towards precision medicine and personalized therapies has been a game-changer for the healthcare industry, and its intersection with the RNAi technology market is proving to be a potent combination. Precision medicine seeks to tailor medical care to the individual, considering their genetic makeup, environment, and lifestyle. This approach stands in stark contrast to the traditional "one-size-fits-all" model and promises better treatment outcomes by addressing the unique genetic underpinnings of a patient's condition. RNA interference (RNAi) technology, with its ability to regulate or silence specific genes, fits seamlessly into this personalized medical model. RNAi technology's inherent capability to target distinct genes allows researchers and clinicians to modulate the expression of genetic markers associated with diseases, making it possible to develop therapies tailored to individual patient profiles. For instance, certain cancer subtypes might be driven by specific genetic mutations. RNAi can be employed to target these mutations, providing therapeutic solutions that are more effective and cause fewer side effects than broad-spectrum treatments.

Moreover, as genetic sequencing becomes more accessible and affordable, the combination of genomic data with RNAi technology will further enhance the potential for targeted and personalized treatments. Identifying genetic susceptibilities or mutations in individual patients and designing RNAi-based therapeutics to address those specific genetic markers can lead to more precise and successful interventions. This convergence of precision medicine with RNAi technology is spurring significant investments and research in the biotech and pharmaceutical sectors.

RNAi in Functional Genomics and Drug Discovery

RNA interference (RNAi) has emerged as an indispensable tool in functional genomics and drug discovery, making a substantial impact on the Global RNAi Technology Market. This revolutionary technology allows researchers to selectively silence or regulate the expression of specific genes, opening up new avenues for understanding gene function, identifying drug targets, and expediting drug development. In the realm of functional genomics, RNAi has become an invaluable asset. Researchers can systematically silence individual genes in model organisms or cell cultures to uncover their roles in various biological processes. This powerful technique helps decipher intricate gene networks, signaling pathways, and regulatory mechanisms. It enables scientists to uncover potential therapeutic targets, map out disease mechanisms, and identify critical genes involved in cancer, neurodegenerative diseases, and other complex disorders. As a result, RNAi technology accelerates the pace of scientific discovery, fueling innovation in genomics research.

Furthermore, RNAi technology has reshaped the landscape of drug discovery. It offers a more efficient and cost-effective approach to validate drug targets, screen potential compounds, and assess their efficacy. By using RNAi to silence the expression of a specific gene associated with a disease, researchers can determine whether the target gene plays a crucial role in the disease process. This approach reduces the likelihood of investing resources in drug development projects that are less likely to succeed, ultimately saving time and money.The potential of RNAi in drug discovery extends beyond target validation. It also enables the development of RNAi-based therapeutics, which have gained considerable attention in recent years. Pharmaceutical companies are actively exploring RNAi as a means to develop novel drugs with higher specificity and fewer side effects.

Segmental Insights

Type Insights

Based on the Type, the Small interfering RNA (siRNA) segment emerged as the dominant segment in the global market for Global RNAi Technology Market in 2022. siRNAs are designed to specifically target and silence individual genes with a high degree of precision. This specificity is crucial in therapeutic applications and functional genomics, where accurate gene modulation is essential.

Application Insights

Based on the Application, the Therapeutics segment emerged as the dominant player in the global market for Global RNAi Technology Market in 2022. Chronic diseases such as cancer, diabetes, cardiovascular disorders, and neurodegenerative conditions are on the rise worldwide. RNAi-based therapeutics hold great promise in treating these diseases by specifically targeting the genetic drivers of these conditions.

Regional Insights

North America emerged as the dominant player in the global RNAi Technology Market in 2022, holding the largest market share. This is on account of the advanced healthcare infrastructure, strong biotechnology and pharmaceutical sector and government support and funding of the region.

Key Market Players

• Alnylam Pharmaceuticals, Inc

• Ionis Pharmaceuticals, Inc.

• Atalanta Therapeutics

• Phio Pharmaceuticals

• Benitec Biopharma

• Novartis AG

• AstraZeneca

• Silence Therapeutics

• Arbutus Biopharma

• Sylentis S.A.

Report Scope:

In this report, the Global RNAi Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global RNAi Technology Market, By Type:

• Micro RNA
• Small interfering RNA
• Others

Global RNAi Technology Market, By Application:

• Treatment Type
• Therapeutics
• Drug Delivery
• Agriculture
• Others

Global RNAi Technology Market, By End User:

• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

Global RNAi Technology Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global RNAi Technology Market.

Available Customizations:

• Global RNAi Technology Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNAi Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Micro RNA, Small interfering RNA, Others)
  • 5.2.2. By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others)
  • 5.2.3. By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America RNAi Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNAi Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico RNAi Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada RNAi Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe RNAi Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France RNAi Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany RNAi Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom RNAi Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy RNAi Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain RNAi Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific RNAi Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNAi Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India RNAi Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea RNAi Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan RNAi Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia RNAi Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America RNAi Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNAi Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina RNAi Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia RNAi Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa RNAi Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa RNAi Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia RNAi Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE RNAi Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global RNAi Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Alnylam Pharmaceuticals, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Current Capacity Analysis
  • 15.1.5. Financials (In case of listed)
  • 15.1.6. Recent Developments
  • 15.1.7. SWOT Analysis
• 15.2. Ionis Pharmaceuticals, Inc.
• 15.3. Atalanta Therapeutics
• 15.4. Phio Pharmaceuticals
• 15.5. Benitec Biopharma
• 15.6. Novartis AG
• 15.7. AstraZeneca
• 15.8. Silence Therapeutics
• 15.9. Arbutus Biopharma
• 15.10. Sylentis S.A.

16. Strategic Recommendations